Defense Health Agency Contracting Activity - DHACA

Description

The ARP CTA supports clinical trials with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism cannot be used for preclinical research studies. Refer to the Application Instructions and General Information, Appendix 6, for helpful information about distinguishing clinical trials and clinical research. The proposed clinical trial is expected to begin no later than 12 months after the award date. Areas of Interest (Revised for FY09): The FY09 ARP encourages applications that address critical needs of the autism community in the following areas:• Co-morbidity: (e.g., manifestations such as disorders [gastrointestinal, sleep, behavioral, speech/language], psychiatric, seizures, immune dysfunction, motor and sensory deficits, metabolic dysfunction, and effects of ASD on intellectual ability)• Predictors for Treatment Outcome: Identification of biomarkers, clinical characteristics, or other phenotypic markers that predict outcomes of a treatment (traditional or complementary and alternative), or populations that will or will not respond to a treatment.

Who can apply

• Unrestricted

Contact

PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil <br/>eReceipt HELP: 301-682-5507; help@cdmrp.org <br/>
cdmrp.pa@amedd.army.mil